ELI LILLY & Co is 408.9x more valuable than SUPERNUS PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $2.62 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SUPN | LLY |
|---|---|---|
| Market cap | $2.62 B | $1.070 T |
| US-listed rank | #1908 | #10 |
| Revenue (latest FY) | $718.95M | $65.18B |
| Net income (latest FY) | -$38.60M | $20.64B |
| Net margin | -5.4% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 1,154 | 989 |
ELI LILLY & Co is 408.9x more valuable than SUPERNUS PHARMACEUTICALS, INC. by market capitalization ($1.070 T vs $2.62 B).
In their latest fiscal years, SUPERNUS PHARMACEUTICALS, INC. reported $718.95M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: SUPERNUS PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.